- Home
- TGTX vs NE Comparison
TGTX vs NE Comparison
Compare TGTX & NE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGTX | NE |
|---|---|---|
| Founded | 1993 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | TGTX | NE |
|---|---|---|
| Price | $30.92 | $32.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $54.75 | $32.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 11-03-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 6.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.78 | 1.40 |
| Revenue | $531,898,000.00 | ★ $3,283,999,000.00 |
| Revenue This Year | $82.31 | $14.57 |
| Revenue Next Year | $49.05 | N/A |
| P/E Ratio | ★ $11.08 | $23.39 |
| Revenue Growth | ★ 100.88 | 24.12 |
| 52 Week Low | $25.28 | $17.40 |
| 52 Week High | $46.48 | $35.06 |
Technical Indicators
Market Signals| Indicator | TGTX | NE |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 63.97 |
| Support Level | $30.54 | $30.26 |
| Resistance Level | $32.26 | $33.66 |
| Average True Range (ATR) | 1.09 | 1.24 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 17.47 | 82.65 |
Price Performance
Historical ComparisonAbout TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.